Semarion
Web Design · Biotechnology
$6.5Mtotal raised · 2 rounds on record
$3.8Mlatest round · Venture round · Mar 2026 · 7 mo ago
2backers · Cambridge Enterprise, Parkwalk Advisors
21stories in the press
Overview
SemaCyte microcarriers turn adherent cells into barcoded, assay-ready reagents for higher throughput & standardisation on existing equipment.
Funding and backers
Total raised
$6.5M
2 rounds on record
Latest round
$3.8M
Venture round · Mar 2026 · 7 mo ago
Backers
2
Cambridge Enterprise, Parkwalk Advisors
The money's age
Fresh money
7 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 31
Raised a round Venture round $3.8M
Jul 9, 2025
Partnership SPT Labtech and Semarion Collaborate to Advance Automated Cell-Based Assay Workflows · semarion.com
Mar 31, 2025
Recognition Semarion Win's SLAS's New Product Award in San Diego · semarion.com
Jun 10, 2024
Recognition Semarion Wins SLAS Europe Ignite Award for Most Innovative Life Science Technology Start-Up · semarion.com
Mar 19, 2024
Launched Semarion Introduces SemaCyte Multiplexing Platform to Enhance Cell Assay Data Quality and Speed During Drug Discovery · semarion.com
Feb 22, 2022
Raised a round Seed $2.7M · FinanzNachrichten.de
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Mar 2026 | $3.8M | — | semarion.com |
| Seed | Feb 2022 | $2.7M | — | FinanzNachrichten.de |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Your browser does not support the video tag. Aglocell SmartMax Overview Aglocell offers a patented, AI-driven software overlay that…
Call today on: 07919 577 658 Email:[email protected] Get a website quote Mobile Ready Ecommerce Websites Find out more about our…
Empowering agencies and marketing teams to create, launch and manage website experiences no code / low code.
Use AI to generate interactions, perfect them credit-free, and hand off clean specs.
Passenger Assistance is an easy-to-use travel app and website designed for Disabled and older people to request their assistance in advance.
Let Fisherman run your entire website and e-commerce with 0 effort. Built for Small Businesses. Low cost, easy to use, and high quality.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Cambridge EnterpriseVia a fund
Parkwalk AdvisorsVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Technology Network Interview: Making Adherent Cell Assays AI-Ready for Next Generation Drug Discovery
The post Technology Network Interview: Making Adherent Cell Assays AI-Ready for Next Generation Drug Discovery appeared first on Semarion.
Read more
Report
Semarion: University of Cambridge Spin-Out Raises $3.8 Million To Scale Cell Assay Technology For Drug Discovery
Semarion, a University of Cambridge spin-out focused on advancing cell-based research, announced it has raised $3.8 million to expand its next-generation cell assay technology and accelerate adoption across the pharmaceutical industry. The funding round w
Read more
Report
Semarion secures $3.8 million to scale next-generation cell assay technology and accelerate pharma adoption
Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today announced it has raised $3.8 million USD (£2.9 million GBP).
Read more
Report
Report
Report
Semarion Secures $3.8 Million to Scale Next-Generation Cell Assay Technology and Accelerate Pharma Adoption
Semarion raises $3.8M to scale its SemaCyte platform, enabling multiplexed, assay-ready adherent cells for faster, data-rich drug discovery.
Read more
Report
Revvity expands SemaCyte multiplexing workflows across Harmony and Signals Image Artist
We are excited to share a set of milestones from our collaboration with Revvity that make SemaCyte multiplexing even easier to adopt across high content imaging teams. A new SemaCyte analysis building block in Harmony and Signals Image Artist Revvity has
Read more
Report
Podcast spotlight: Tarun Vemulkar on "Science in Real Time" with Araceli Biosciences
We are excited to share that Semarion's co-founder and CTO, Dr Tarun Vemulkar, was featured on Araceli Biosciences' "Science in Real Time" podcast in Episode 6 (Spotlight), a conversation hosted by Carli Reyes on how Semarion is rethinking adherent cell h
Read more
Report
SPT Labtech and Semarion Collaborate to Advance Automated Cell-Based Assay Workflows
Press Release 09 July 2025 SPT Labtech and Semarion Collaborate to Advance Automated Cell-Based Assay Workflows Integration of firefly liquid handling platform and SemaCyte microcarriers enables flexible, miniaturized, and automated cell assay workflows C
Read more
Report
Video Interview at SLAS 2025 Accelerating Drug Discovery with SemaCyte Technology
In this short interview from SLAS 2025 in San Diego, Semarion CEO Jeroen Verheyen shares how Semarion is solving key bottlenecks in in vitro drug discovery. Semarion is pioneering a new materials platform to accelerate the generation of high-quality biolo
Read more
Report
Show more news